The trial is evaluating EB103, which is a CD19-redirected ARTEMIS® T-cell therapy, in adult patients (aged 18 and older) with ...

Design Using the UK Clinical Practice Research Datalink, we conducted a population-based cohort study using a new-user active comparator design. From 1 January 1990 to 30 April 2018, we identified 973 ...